Abstract:OBJECTIVE:To evaluate the potential role of tegaserod in the management of functional dyspepsia (FD) and gastroesophageal reflux disease (GERD) in patients with chronic constipation and to determine the possible efficacy of tegaserod on solid-phase gastric emptying and gastric hypersensitivity.METHOD:This was an exploratory open-label trial of tegaserod therapy for dyspepsia and reflux symptoms in patients with chronic constipation. The study cohort consisted of 90 patients randomized to three treatment groups for a study period of 4 weeks (tegaserod 6 mg, twice daily; esomeprazole 40 mg, once daily; tegaserod 6 mg, twice daily plus esomeprazole 40 mg, once daily). Twenty healthy volunteers provided control values. Clinical symptoms were evaluated by one of the investigators using a Gastrointestinal Symptom Rating Scale (GSRS). Solid-phase gastric emptying and colonic transit were measured by the radiopaque barium marker method, and the water load test (WLT) was used to evaluate gastric sensation and the function of proximal stomach. The proportions of patients with complete relief of epigastric pain /discomfort, epigastric fullness, early satiety and heartburn in the tegaserod group and the tegaserod plus esomeprazole group were compared with the esomeprazole group, respectively.RESULTS:The mean global gastrointestinal (GI) scores of all three treatment groups reported using the GSRS showed the same trend, with decreasing scores over the 4-week study period indicating a reported decreasing severity of symptoms that was significantly different from baseline values. Patients in the tegaserod plus esomeprazole group reported the lowest global GI scores after 4 weeks, as expected. Solid-phase gastric emptying (GER) and colonic transit (CTT) increased significantly in the tegaserod 6 mg twice daily group compared with baseline. These parameters did not change in the esomeprazole group at week 4 compared with baseline. In terms of gastric sensation, in the tegaserod group, the proportions of patients with hypersensitivity of the first perception threshold did not change at week 2 or week 4 compared with baseline; however, in this group and in the tegaserod plus esomeprazole group, the proportions of patients with hypersensitivity of discomfort threshold decreased significantly at week 4 compared with baseline. In the esomeprazole group, there were no changes in the proportions of patients with hypersensitivity of the first perception threshold and discomfort threshold at week 2 or 4 compared with baseline. No severe adverse events were recorded, and the medications were in general well-tolerated.CONCLUSION:Tegaserod is effective and safe at improving dyspepsia and reflux symptoms in patients with chronic constipation, and tegaserod plus esomeprazole is superior to esomeprazole alone in the resolution of epigastric pain/discomfort and heartburn.

A Selective 5-Ht4 Receptor Antagonist Blocks The Effect Of Tegaserod On Rat Inferior Splanchnic Afferents In Vitro

Sacral nerve stimulation with appropriate parameters improves constipation in rats by enhancing colon motility mediated via the autonomic-cholinergic mechanisms.

Effects of tegaserod on visceral sensitivity and expression of SP and CGRP in the rat colon

Effects of Tegaserod on Fos, Substance P and Calcitonin Gene-Related Peptide Expression Induced by Colon Inflammation in Lumbarsacral Spinal Cord

Tegaserod inhibits noxious rectal distention induced response and spinal nNOS expression in rats with visceral hypersensitivity

Tegaserod Inhibits Noxious Rectal Distention Induced Responses and Limbic System C-Fos Expression in Rats with Visceral Hypersensitivity

Effect of Tegaserod on the Serotonin Content in Rat Ileocaecal Mucosa under Partial Restraint Stress

Effects of Tegaserod on Dyspeptic Symptoms, Electrogastrography, Gastrointestinal Transit and Anorectal Function in Chronic Constipation

Oral Ingestion of a 5-HT4 Receptor Agonist Evokes a CNS-ENS Mediated Gastro-Colonic Reflex Involving High Amplitude Propulsive Contractions (hapcs) in the Human Colon Within 5 Minutes

Effects of tegaserod on spinal c-Fos expression in rats with visceral hypersensitivity after rectal distention

Short-Term Effects of Relamorelin on Descending Colon Motility in Chronic Constipation: A Randomized, Controlled Trial

Mechanisms of Gastroesophageal Reflux in Critically III Mechanically-Ventilated Patients

Influence of Tegaserod on the Changes of Autonomic Tone Induced by Colorectal Distension in Rats

Tegaserod for Dyspepsia and Reflux Symptoms in Patients with Chronic Constipation: an Exploratory Open-Label Study

Effect of progesterone on colonic motility and fecal output in mice with diarrhea

Enhanced Contractive Tension and Upregulated Muscarinic Receptor 2/3 in Colorectum Contribute to Constipation in 6-Hydroxydopamine-induced Parkinson's Disease Rats.

Effects of Sennoside A on Intestinal Motility in Rats with Colonic Slow Transit Constipation

Supraspinal inhibitory effects of chimeric peptide MCRT on gastrointestinal motility in mice.

Changes of spinal evoked potentials and cerebral evoked potentials in visceral hypersensitivity rats before and after Tegaserod treatment

The 5HT4R agonist velusetrag efficacy on neuropathic chronic intestinal pseudo-obstruction in PrP-SCA7-92Q transgenic mice

Role of Enteric Nerves in the Regulation and Propagation of Spontaneous and Electrically “paced” Gastric Slow Waves in Rats